Christopher Graybill Joins ARCA as Vice President, Clinical Development
05 mai 2021 16h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Anticoagulant Reversal Drugs Market to Garner $2,276.54 Million by 2027 | 12.6% CAGR - Impact of COVID-19 Pandemic and Global Analysis by The Insight Partners
07 avr. 2021 10h00 HE
|
The Insight Partners
Pune, India, April 07, 2021 (GLOBE NEWSWIRE) -- According to our new research study on “Anticoagulant Reversal Drugs Market to 2027 – Global Analysis and Forecast – by Product and Distribution...
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
19 janv. 2021 08h05 HE
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
10 déc. 2020 04h13 HE
|
Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020
13 nov. 2020 10h00 HE
|
InCarda Therapeutics, Inc.
Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhythmic for Treatment of...
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
21 oct. 2020 08h05 HE
|
InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
North America Implantable Loop Recorders Market Report 2020 Featuring Medtronic, Abbott Laboratories, Boston Scientific, BIOTRONIK SE & Co, Angel Medical Systems, Vectorious Medical Technologies
21 sept. 2020 05h08 HE
|
Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "North America Implantable Loop Recorders Market By Application (Atrial fibrillation, Cardiac Arrhythmia and Cardiac syncope), By End User (Hospitals,...
CoreMap Completes $10.5 Million Series A Financing
16 sept. 2020 08h00 HE
|
CoreMap, Inc.
BURLINGTON, Vt., Sept. 16, 2020 (GLOBE NEWSWIRE) -- CoreMap announced today it has completed a $10.5 million Series A financing led by Qure Ventures. The round included both existing investors such...
CoreMap Wins National Science Foundation Phase I SBIR Award
08 sept. 2020 11h52 HE
|
CoreMap, Inc.
BURLINGTON, Vt., Sept. 08, 2020 (GLOBE NEWSWIRE) -- CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science...
$1.3 Billion AI in Diagnostics Industry Assessment 2020-2026 by Diagnosis Type, Component and Region
26 août 2020 08h21 HE
|
Research and Markets
Dublin, Aug. 26, 2020 (GLOBE NEWSWIRE) -- The "Global Artificial Intelligence in Diagnostics Market By Diagnosis Type (Radiology, Oncology, Neurology, Cardiology, Chest & Lungs, Pathology and...